Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | 2 | 2 | — | — | — | 4 |
Esophagitis | D004941 | HP_0100633 | K20 | — | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pharmacokinetics | D010599 | — | — | 3 | — | — | — | — | 3 |
Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
Drug common name | LINAPRAZAN |
INN | linaprazan |
Description | Linaprazan is an experimental drug for the treatment of gastroesophageal reflux disease (GERD). Unlike the proton-pump inhibitors (PPIs) which are typically used to treat GERD, linaprazan is a potassium-competitive acid blocker (P-CAB). Linaprazan was developed by AstraZeneca, but it was not successful in clinical trials.
|
Classification | Small molecule |
Drug class | proton pump inhibitors, not dependent on acid activation |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12 |
PDB | — |
CAS-ID | 248919-64-4 |
RxCUI | — |
ChEMBL ID | CHEMBL497011 |
ChEBI ID | — |
PubChem CID | 9951066 |
DrugBank | — |
UNII ID | E0OU4SC8DP (ChemIDplus, GSRS) |